Amylyx Pharmaceuticals In... (AMLX)
Amylyx Pharmaceuticals Inc. (AMLX) Stock Price, Analysis & Data
| Geld | n/a |
| Marktkapitalisierung | 3.91 Mrd |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -152.09 Mio |
| Beta | -0.20 |
| EPS (ttm) | -2.31 |
| KGV (TTM) | n/a |
| Forward-KGV | -25.33 |
| KBV (TTM) | 16.35 |
| KUV (TTM) | n/a |
| Earnings Date | Nov 5, 2026 |
| Brief | n/a |
| Volumen | 23,606,658 |
| Ø Vol. (20D) | 2,043,522 |
| Eröffnung | 29.93 |
| Vortagesschluss | 21.43 |
| Tagesspanne | 28.00 - 35.39 |
| 52-Wk Range | 7.63 - 35.39 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also devel...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Amylyx Pharmaceuticals 0, ein Rückgang von -100% im Vergleich zum Vorjahr (87.37 Mio). Der Gewinn lag bei -144.74 Mio, ein Rückgang von -52.03 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 12 Stunden · Insider Monkey
Amylyx (AMLX) Climbs to Fresh High as Avexitide Moves Closer to CommercializationAmylyx Pharmaceuticals Inc. (NASDAQ:AMLX) soared to a new three-year high on Tuesday after its treatment candidate for post-bariatric hypoglycemia (PBH) reported strong results in phase 3 clinical stu...
vor 12 Stunden · Motley Fool
Why Amylyx Pharmaceuticals Stock Skyrocketed TodayGLP-1 drugs aren't just for weight loss.
